 | | Vol. 11.42 – 16 November, 2022 |
| |
|
|
| Investigators evaluated the performance of unsupervised clustering for the post-induction assessment of bulk and leukemic stem cells measurable residual disease in 155 acute myeloid leukemia patients who received intensive conventional chemotherapy treatment.
[Clinical Cancer Research] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors presented exploratory analyses on the use of circulating tumor DNA testing as an additional method to identify castration-resistant prostate cancer patients with homologous recombination repair gene alterations who may be eligible for olaparib treatment.
[Clinical Cancer Research] |
|
|
|
| Using a spontaneous model of mammary carcinoma, investigators identified bone marrow (BM) mesenchymal stem cells as the first sensors of distal cancer cells and key mediators of BM reprogramming.
[Cancer Research] |
|
|
|
| Scientists demonstrated that Plasmacytoma Variant Translocation-1 (PVT-1) was critical for osteosarcoma tumor-initiation potential, further elucidating the role of PVT-1 in the enhancement of cancer stem-like behaviors
[Oncogene] |
|
|
|
| Researchers demonstrated that glioma stem cells (GSCs) lacking epidermal growth factor receptor (EGFR) amplification are exquisitely sensitive to de novo pyrimidine synthesis perturbations, while GSCs that amplify EGFR were utterly resistant.
[Oncogene] |
|
|
|
| While HoxA9 alone immortalizes cells, cooperation with Meis1 is necessary to induce a full leukemic phenotype. The authors applied degron techniques to elucidate the leukemogenic contribution of Meis1.
[Haematologica] |
|
|
|
| Researchers identified miR-637 as a Wiskott-Aldrich syndrome protein and SCAR Homolog (WASH)-targeting miRNA. miR-637 mimic strongly attenuated the downstream IL-8 production and tumor sphere formation in esophageal cancer cells, whereas miR-637 inhibitor displayed an opposite effect.
[Biomarker Research] |
|
|
|
| The authors identified melanoma cell lines lacking SOX10 expression which retain their in vivo growth capabilities.
[iScience] |
|
|
|
| Investigators performed single-nucleus transcriptomics of mutant and wild-type glioma samples sorted for Sox2 stem cell marker.
[Scientific Reports] |
|  |
|
|
|
| Scientists review recent research findings that provide a mechanistic link between the commonly deregulated transcription factors and stemness in cancer.
[Seminars in Cancer Biology] |
|
|
|
|
| SELLAS Life Sciences Group, Inc. announced important updates relating to its ongoing Phase III open-label registrational clinical trial for galinpepimut-S in acute myeloid leukemia patients who have achieved complete remission following second-line salvage therapy.
[SELLAS Life Sciences Group, Inc.] |
|
|
|
| Monash Biomedicine Discover Institute (BDI) researcher, Dr. Thierry Jardé has been awarded a Victorian Cancer Agency 2022 Mid-Career Research Fellowship to further his research into developing new treatment approaches against advanced bowel cancer.
[Monash University] |
|
|
|
|
| February 19 – 22, 2023
Banff, Alberta, Canada |
|
|
|
|
|
| | AstraZeneca – Waltham, Massachusetts, United States |
|
|
|
| | STEMCELL Technologies, Inc. – Boston, Massachusetts, United States |
|
|
|
| | Cancer Research UK Manchester Institute – Manchester, England, United Kingdom |
|
|
|
| | Johannes Kepler University of Linz – Linz, Austria |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
